A Stochastic Approach to LDL-C Intensification
Keywords:
LDL-C, lipid intensification therapy, clinical benefitAbstract
The transition from general guidelines to precision cardiovascular medicine requires tools that can model individual biological variance. This paper outlines the methodology of LipidLogic Pro v2.1, a simulation engine for predicting Absolute Risk Reduction (ARR) and Number Needed to Treat (NNT) following intensified lipid-lowering therapy. The engine utilizes a kinetic-based meta-regression approach derived from the Cholesterol Treatment Trialists’ (CTT) Collaboration.
References
1. Baigent C, et al. (Cholesterol Treatment Trialists’ Collaboration). Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet. 2005;366(9493):1267-1278
2. Cannon CP, et al. (IMPROVE-IT Investigators). Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387-2397.
3. Mach F, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias : lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-188.
4. Sabatine MS, et al. (FOURIER Steering Committee). Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-1722.
Downloads
Published
Versions
- 2025-12-09 (3)
- 2026-06-12 (2)
- 2025-12-09 (1)
Issue
Section
License
Copyright (c) 2025 Khaing Mar Lwin, Mahmood Ahmad, Tomi, Ata Ul Hayee Sohail
This work is licensed under a Creative Commons Attribution 4.0 International License.
Articles in Synthesis are published under the Creative Commons Attribution 4.0 International (CC BY 4.0) licence. Authors retain copyright.
